Roche Scientific Company India Private Limited

What Roche Scientific Company India Private Limited does

Roche Scientific Company India Private Limited is the Indian operating subsidiary of Swiss-headquartered Roche Group, incorporated in 1994 as a wholly-owned subsidiary and marketed as "Roche India" / "Roche Pharma India." The company markets a portfolio of innovative pharmaceutical products across six core therapeutic areas: oncology (Tecentriq, Perjeta, Herclon/Trastuzumab, Kadcyla, Avastin, Alecensa, Rozlytrek, Polivy, PHESGO), hematology/hemophilia (Hemlibra), rare diseases (Evrysdi for Spinal Muscular Atrophy), neurology (Ocrevus for Multiple Sclerosis), ophthalmology (Vabysmo for retinal disorders), and immunology/transplantation/nephrology (Actemra, Ristova, CellCept, Mircera, NeoRecormon). Its product mix emphasizes first-in-class or differentiated biologics, including bispecific antibodies, antibody-drug conjugates, and subcutaneous formulations that improve administration convenience.

The company's commercial model is a hybrid of direct enterprise field sales organized into regional clusters (each led by a Chief Operating Officer) and channel partnerships — most notably the Cipla distribution agreement covering key trademark oncology drugs (Herclon, Avastin, Ristova) signed in June 2020 and built on a 2018 Tocilizumab arrangement. Beyond drug commercialization, Roche India invests in patient access infrastructure, including The Blue Tree patient support program (7,000+ patient lives impacted across 11 services) and partnerships with government bodies (e.g., Punjab Department of Health), medical societies (VRSI, MSSI), and technology providers (Niramai, Karkinos, ZS Associates). It also operates a state-of-the-art Offshore Development Center (YODAc) in Chennai with ZS Associates consolidating data and analytics operations across all Roche Pharma affiliates, and a Customer Experience Center inaugurated in August 2024.

Revenue mechanics are driven by prescription pharmaceutical sales through hospitals, cancer centers, specialty clinics, and government/healthcare system procurement. Pricing is not publicly disclosed and is negotiated through institutional channels and reimbursement frameworks (including Ayushman Bharat PM-JAY assessments). The company monetizes through one-time product sales of high-value specialty biologics and supplements revenue with ecosystem investments — patient support programs, awareness campaigns (Walk In My Shoes, Mission Vision, Pink Project), and academic initiatives (LEAP Oncology/Ophthalmology) — designed to drive earlier diagnosis, treatment adoption, and stakeholder engagement across India's healthcare ecosystem.

Name

Roche Scientific Company India Private Limited

Legal name

Roche Products (India) Private Limited

Website

https://rocheindia.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1–10 employees

Short description

Roche Scientific Company India Private Limited is the Indian subsidiary of Swiss-headquartered Roche Group, marketing innovative biologics and pharmaceuticals across oncology, hemophilia, rare diseases, neurology, ophthalmology, and immunology, distributed via a cluster-based field sales model and channel partnerships including Cipla.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Oncology, Hematology, Rare Diseases, Neuroscience, Ophthalmology, Transplantation, Nephrology)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Oncology pharmaceuticals
• Biologics manufacturing
• Hematology treatments
• Rare disease therapies
• Patient support programs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Roche generates revenue through the sale of prescription pharmaceutical medicines including oncology drugs, biologics, and specialty treatments across therapeutic areas such as oncology, hematology, rare diseases, neurology, and ophthalmology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels11 records

Core offering

Roche Scientific Company India Private Limited develops, markets, and distributes innovative prescription pharmaceutical medicines and biologics across oncology, hematology, hemophilia, rare diseases, neuroscience, ophthalmology, transplantation, and nephrology therapeutic areas in India. Its portfolio includes targeted therapies, immunotherapies, antibody-drug conjugates, bispecific antibodies, and subcutaneous formulations. The company also operates The Blue Tree Program, providing 11 patient support services including free and subsidized drug support, diagnostics funding, treatment funding, documentation support, and post-treatment assistance, which has impacted more than 7,000 patient lives.

Product overview

Roche Scientific Company India Private Limited offers a comprehensive portfolio of innovative pharmaceutical products across six core therapeutic areas: Ophthalmology (Vabysmo for retinal disorders), Neuroscience (Ocrevus for Multiple Sclerosis), Oncology (Tecentriq, Perjeta, Herclon, Kadcyla, Avastin, Alecensa, Rozlytrek, Polivy, PHESGO), Rare Diseases (Evrysdi for Spinal Muscular Atrophy), Hematology/Hemophilia (Hemlibra), and Rheumatology/Nephrology/Transplantation (Actemra, Ristova, CellCept, Mircera, NeoRecormon). The company also provides patient support through The Blue Tree Program offering 11 services including subsidized medicines, and operates data analytics centers in partnership with ZS Associates. Products are distributed through partnerships including Cipla for key oncology medicines, and the company supports healthcare access through various patient assistance and CSR initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• The Blue Tree Program: Patient support initiative for cancer, hemophilia and rare disease patients offering 11 services including free and subsidized drug support. Has impacted 7000+ patient lives.
• LEAP (Leading Engagements to Advance Patient Care)
• LEAP Oncology
• LEAP Ophthalmology
• Mission Vision
• Walk In My Shoes

Products and services

• Tecentriq (Atezolizumab) Anti-PD-L1 monoclonal antibody and cornerstone of Roche's cancer immunotherapy portfolio, approved for metastatic NSCLC, extensive-stage SCLC, triple-negative breast cancer, hepatocellular carcinoma, and metastatic urothelial carcinoma. Used by oncologists and hospital oncology centers for cancer patients across multiple tumor types.
• Tecentriq Subcutaneous World's first subcutaneous immunotherapy for lung cancer. Delivers the same efficacy as IV Tecentriq in approximately 7 minutes, reducing chair time by 60%, and is preferred by 71% of patients. Approved in 62 countries including US FDA and EMA, for use by oncology infusion centers.
• Perjeta (Pertuzumab) HER2-targeted therapy for HER2+ breast cancer. Binds to a different side of the HER2 receptor than Herceptin, providing complementary dual blockade, and is administered together with Herceptin for increased efficacy. Approved in over 80 countries. Used by oncologists and breast cancer treatment centers.
• Herclon (Trastuzumab) HER2-targeted monoclonal antibody for HER2+ breast cancer. Part of Roche's HER2 franchise and distributed in India through the Cipla partnership since June 2020. Used by oncologists and cancer centers treating HER2+ breast cancer.
• Kadcyla (Ado-trastuzumab emtansine) First FDA-approved antibody-drug conjugate (ADC) for HER2-positive metastatic breast cancer and adjuvant early breast cancer. Approved in 113 countries worldwide with 300,000+ patients treated globally. Used by oncology centers treating HER2+ breast cancer.
• Avastin (Bevacizumab) Anti-VEGF monoclonal antibody and foundational anti-angiogenic therapy for advanced cancers since 2004. Approved in 130+ countries for metastatic colorectal cancer, NSCLC, renal cell carcinoma, glioblastoma, ovarian cancer, and cervical cancer. Used by oncologists treating multiple solid tumors.
• Alecensa (Alectinib) ALK tyrosine kinase inhibitor (TKI) for ALK-positive non-small cell lung cancer (NSCLC). Selectively targets ALK phosphorylation to induce tumor cell apoptosis and transforms the standard of care in ALK+ NSCLC. Used by lung cancer specialists and oncology centers.
• Rozlytrek (Entrectinib) Kinase inhibitor for ROS1-positive NSCLC and NTRK fusion-positive tumors. Indicated for adult patients with locally advanced or metastatic ROS1-positive NSCLC and for adult and pediatric patients aged 12 and above with NTRK gene fusion-positive solid tumors. Used by oncologists treating these molecularly defined solid tumors.
• Polivy (Polatuzumab Vedotin) First-in-class CD79b-directed antibody-drug conjugate (ADC) for diffuse large B-cell lymphoma (DLBCL) and the first DLBCL therapy in two decades to improve progression-free survival compared to standard of care. Approved in over 80 countries with 10,000+ 1L DLBCL patients treated. Used by hematologists and oncology centers.
• PHESGO World's first ready-to-use, fixed-dose subcutaneous injection combining Perjeta and Herceptin with hyaluronidase. Reduces patient time in hospital by up to 90% and is administered in minutes versus hours for IV administration. Impacted over 16,000 patients globally since launch. Used by oncology centers for HER2+ breast cancer.
• Hemlibra (Emicizumab) Prophylactic treatment for Hemophilia A and the only approved subcutaneous hemophilia A treatment that can be self-administered. Prevents or reduces bleeding episodes across all age groups with flexible dosing options (weekly, every two weeks, or every four weeks). Approved in more than 100 countries with 15,000+ patients treated globally. Used by hematologists and hemophilia treatment centers, particularly for children with Hemophilia A given the IV factor VIII burden.
• Evrysdi (Risdiplam) Oral SMN2 splicing modifier for the treatment of Spinal Muscular Atrophy (SMA). The only oral therapy for SMA patients across all types, aged 2 months and older. Approved in 108 countries with 16,000+ patients treated globally. Used by neurologists and rare disease specialists treating SMA.
• Ocrevus (Ocrelizumab) Anti-CD20 B-cell targeting therapy for Multiple Sclerosis. The first and only therapy approved for both relapsing forms of MS (RMS including RRMS and active SPMS) and primary progressive MS (PPMS), with twice-yearly dosing. Approved in over 110 countries. Used by neurologists treating Multiple Sclerosis patients.
• Vabysmo (Faricimab) The first bispecific antibody approved for the eye, targeting Angiopoietin-2 (Ang-2) and VEGF-A pathways to treat neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). Provides extended dosing intervals up to 4 months with up to 33% fewer injections required over two years. Used by retina specialists and ophthalmology centers.
• Actemra (Tocilizumab) IL-6 receptor antagonist for Rheumatoid Arthritis and COVID-19. Available in IV and subcutaneous formulations. Distributed to hospitals, rheumatology centers, and critical care units treating moderate-to-severe rheumatoid arthritis and cytokine release syndromes.
• Ristova (Rituximab) Anti-CD20 monoclonal antibody for hematologic malignancies and autoimmune diseases. Distributed in India through the Cipla partnership. Used by hematologists and oncologists treating hematologic malignancies.
• CellCept (Mycophenolate Mofetil) Immunosuppressant for organ transplantation, available in capsules, tablets, and oral suspension formulations for prevention of organ rejection. Used by transplant centers and nephrology departments.
• Mircera (Methoxy polyethylene glycol-epoetin beta) Long-acting erythropoiesis-stimulating agent for anemia associated with chronic kidney disease, providing sustained hemoglobin levels. Used by nephrologists and dialysis centers.
• NeoRecormon (Epoetin beta) Erythropoietin for treatment of anemia in hematology settings. Used by hematology centers treating anemia.
• Ronapreve (Casirivimab and Imdevimab) Neutralizing antibody cocktail for COVID-19 treatment, available in 1200mg IV and subcutaneous administration. Received Emergency Use Authorization in India for treatment of mild to moderate COVID-19 in high-risk patients. Used by hospitals and critical care units.
• The Blue Tree Program Flagship patient support program by Roche Pharma India for cancer, hemophilia, and rare disease patients, providing 11 services including free and subsidized drug support, diagnostics funding, treatment funding, information, post-treatment job search assistance, documentation support for reimbursement, and free medicines. Has impacted 7,000+ patient lives across India.

Quantifiable outcome

• 7000+ patient lives impacted through The Blue Tree Program with 11 services including free and subsidized drug support
• +5 more outcomes

Named customers13 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Partnerships

13 partnerships are on record, tiered core, major and minor.

• ZS AssociatescoreTechnology or Integration · 6 July 2023Roche inaugurated a state-of-the-art Offshore Development Center (ODC) named YODAc (Your One stop shop for Data & Analytics Center) in Chennai in partnership with ZS Associates. The center consolidates data and analytics business operations services of all Roche Pharma affiliates, bringing together capabilities including business data operations, data quality management, global analytical product support. Roche has enjoyed a strong partnership with ZS Associates for over 20 years.
• CiplacoreChannel Partner/ Reseller/ Distributor · 18 June 2020Roche Products (India) Pvt. Ltd. signed a distribution agreement with Cipla to expand the scope of partnership to include marketing and distribution of key trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin), and Rituximab (Ristova) in India. The partnership builds on an earlier February 2018 agreement for Tocilizumab (Actemra) and other products.
• Karkinos HealthcaremajorStrategic or Co-development PartnerRoche partnered with Karkinos - a startup funded by Tata Group and Reliance - to create equitable access to cancer care through innovative technology platforms. The partnership aims to develop uniform standards of patient care through technology-enabled distributed care models, emphasizing early detection, referral strengthening, and standardized care pathways. Implementation planned across five ecosystems in a staggered manner.
• ACCESS Health InternationalmajorStrategic or Co-development PartnerACCESS Health International and Roche India Health Institute (RIHI) joined hands to strengthen access to best cancer treatment, augment awareness generation, timely screening and diagnosis in collaboration with the state government of Uttar Pradesh. Partnership follows a three-pronged approach: assessment of medical oncology landscape under Ayushman Bharat PM-JAY, capacity building for HCPs, and strengthening the State diagnostic and essential drug list.
• Delhi State Cancer Institute (DSCI)majorStrategic or Co-development PartnerRoche Pharma India and Delhi State Cancer Institute (DSCI) signed an MoU to strengthen cancer care capabilities at DSCI and enable delivery of quality and comprehensive cancer care treatment for patients in the DSCI network. The partnership will bolster and close gaps in cancer prevention and management.
• City Cancer ChallengeminorStrategic or Co-development PartnerThrough Roche's decentralized cluster-based model, the Kerala State Cluster participates in the prestigious City Cancer Challenge initiative aimed at improving access to quality cancer care in Kochi city. City Cancer Challenge is a city-based partnership initiative transforming how public and private sector stakeholders collectively design, plan and implement cancer solutions.
• St. Jude India ChildCare CenterscoreStrategic or Co-development PartnerRoche Pharma India partnered with St. Jude India ChildCare Centres to build Roche Children's Centre providing holistic cancer care to children undergoing treatment and their families. Centers in Mumbai and Guwahati offer children up to age 18 undergoing cancer treatment accommodation, transport, education, nutritional support, emotional support and recreational activities. Impact: 350+ children lives touched, 100% treatment completion rate, 100% infection-free.
• Niramai Health Analytix Private LimitedmajorTechnology or IntegrationRoche partnered with Niramai and Punjab Department of Health & Family Welfare for the 'Pink Project' (Punjab Breast Cancer AI-Digital project). The partnership focuses on early detection of breast cancer using Niramai's machine learning algorithms for accurate detection. Target: 15,000 screenings of suspected females within one year with digital referral pathway for diagnosis and treatment initiation.
• Department of Health & Family Welfare, Government of PunjabmajorStrategic or Co-development PartnerGovernment partner in the Pink Project for breast cancer early detection. The Department ensures mobilization of people for screening and coordinates with healthcare facilities for referral pathways.
• Multiple Sclerosis Society of India (MSSI)coreStrategic or Co-development PartnerRoche Pharma India collaborated with the Multiple Sclerosis Society of India (MSSI) to launch 'Walk In My Shoes' - a public health awareness initiative highlighting the invisible struggles of individuals living with MS. The initiative featured interactive kiosks in Delhi, Bengaluru, and Mumbai where over 4500 people experienced MS symptoms simulation.
• Vitreo Retinal Society of India (VRSI)coreStrategic or Co-development PartnerRoche Pharma India partnered with the Vitreo Retinal Society of India (VRSI) and The Times of India (TOI) to launch Mission Vision - a national movement to bring retinal health to the forefront of India's healthcare agenda. The initiative includes VIEW Council bringing together retina specialists, policy makers and public health experts to develop a national roadmap across public awareness, screening & diagnosis, capacity building, and policy advocacy.
• The Times of IndiacoreGTM or Marketing PartnerMedia partner for Mission Vision initiative - a public health movement on retinal health awareness in India. Partnership leverages India's largest media platform to amplify awareness about diabetic retinopathy and other retinal diseases.
• Navya Care (Project Navya)minorStrategic or Co-development PartnerRoche India Healthcare Institute (RIHI) supported 2,000 cancer patients through Navya Care Cancer Patients Hotline - a virtual, guideline-based approach helping patients make informed treatment decisions during the Covid-19 pandemic.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• AbbVie India: Indian affiliate of AbbVie. Direct immunology/oncology peer (Humira biosimilars environment, Imbruvica, Venclexta, Skyrizi) competing for the same rheumatology, hematology and oncology budgets as Roche's CellCept, Actemra and Venclexta-relevant indications.
• Eli Lilly India: Indian affiliate of Eli Lilly. Direct specialty peer with oncology (Verzenio, Cyramza), diabetes (incretins) and neurology assets competing for similar HCP and patient segments; comparable biologic-portfolio strategy and premium-pricing model.
• Novartis India: Indian arm of Novartis AG. Direct peer in specialty pharma with overlapping footprint in ophthalmology (Lucentis/Beovu vs Roche's Vabysmo), neurology (Kesimpta in MS vs Ocrevus), and oncology. Both operate premium-biologic portfolios with similar hospital-channel GTM in India.
• AstraZeneca Pharma India: Indian subsidiary of AstraZeneca. Strong oncology overlap (Tagrisso, Imfinzi, Lynparza, Enhertu) targeting the same Indian oncologist channel as Roche's HER2/PD-L1 franchises. Comparable specialty-pharma commercial model and HCP engagement approach.
• Merck Sharp & Dohme (MSD) India: Indian operations of Merck & Co. Direct peer in oncology (Keytruda competing with Tecentriq) and across specialty pharma, with similar hospital-channel and reimbursement-strategy infrastructure serving India's leading cancer centers.
• Bristol Myers Squibb India: Indian affiliate of BMS. Direct oncology peer with hematology assets (Revlimid, Pomalyst, Empliciti) and immuno-oncology (Opdivo) that compete for the same oncologists and hospital procurement budgets as Roche's Tecentriq, Polivy and Kadcyla.

Others

• Cipla: Roche India's distribution partner for Herclon, Avastin and Ristova, and a leading Indian pharma with strong oncology, respiratory and biosimilars portfolio. Distribution partnership plus broad domestic pharma presence makes Cipla a strategically adjacent rather than directly competing peer.

Broad incumbents

• Johnson & Johnson India (Innovative Medicine): Indian arm of J&J Innovative Medicine. Competes in oncology (Darzalex, Imbruvica, Erleada), hematology and immunology with similar hospital-channel model; broader medtech footprint but directly comparable pharma-commercial infrastructure.
• Pfizer India: Indian operations of Pfizer Inc. Operates across oncology, vaccines, inflammation/immunology and rare diseases with a broader primary-care portfolio than Roche India. Comparable multinational specialty/biologic presence and physician-channel infrastructure.
• Sanofi India: Indian affiliate of Sanofi. Broad specialty and primary-care footprint including oncology, immunology (Dupixent vs Actemra), rare disease (rare blood disorders vs Roche hemophilia) and consumer health. Comparable multinational footprint with cross-therapy portfolio.

Market position

Strengths1 record

Weaknesses1 record

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/roche
• YouTubeyoutube.com/roche
• Facebookfacebook.com/roche
• LinkedInlinkedin.com/company/roche-scientific-company-india-private-limited
• Instagraminstagram.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Scientific Company India Private Limited